Biotransformation of Sildenafil in the Male Rat: Evaluation of Drug Interactions with Testosterone and Carbamazepine

REFERENCES

• A. K. Ashton, and R. G. Bennett. 1999. Sildenafil treatment of serotonin reuptake inhibitor-induced sexual dysfunction. J. Clin. Psychiatry 60:194–195.
   PubMed Web of Science ®Google Scholar
• T. L. Domanski, Y. A. He, G. R. Harlow, and J. R. Halpert. 2000. Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. J. Pharmacol. Exp. Ther. 293:585–591.
   PubMed Web of Science ®Google Scholar
• A. C. Egnell, B. Houston, and S. Boyer. 2003. In vivo CYP3A4 Heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J. Pharmacol. Exp. Ther. 35:1251–1262.
   Google Scholar
• F. P. Guengerich. 2001. Analysis and characterization of enzymes and nucleic acids. In A. W. Hayes (Ed.), Principles and methods of toxicology (4th ed., pp. 1625–1687). Philadelphia: Taylor & Francis.
   Google Scholar
• N. A. Hosea, G. P. Miller, and F. P. Guengerich. 2000. Elucidation of distinct ligand binding sites for cytochrome P450 3A. Biochemistry 39:5929–5939.
   PubMed Web of Science ®Google Scholar
• R. Hyland, E. G. H. Roe, B. C. Jones, and D. A. Smith. 2000. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br. J. Clin. Pharmacol. 51:239–248.
   Web of Science ®Google Scholar
• R. Hyland, E. G. H. Roe, B. C. Jones, and D. A. Smith. 2001. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br. J. Clin. Pharmacol. 51:239–248.
   PubMed Web of Science ®Google Scholar
• K. Kenworthy, S. Clarke, J. Andrews, and J. B. Houston. 2001. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos. 29:1644–1651.
   PubMed Web of Science ®Google Scholar
• A. P. Koley, J. T. M. Buters, R. C. Robinson, A. Markowitz, and F. K. Friedman. 1995. CO binding kinetics of human cytochrome P450 3A4: Specific interaction of substrates with kinetically distinguishable conformers. J. Biol. Chem. 270:5014–5018.
   PubMed Web of Science ®Google Scholar
• K. R. Korzekwa, N. Krishnamachary, M. Shou, R. A. Parise, A. E. Rettie, F. J. Gonzalez, and T. S. Tracy. 1998. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137–4147.
   PubMed Web of Science ®Google Scholar
• H. D. Langtry, and A. Markham. 1999. Sildenafil. Drugs 57:967–989.
   PubMed Web of Science ®Google Scholar
• H. G. Nurnberg, J. Lauriello, P. L. Hensley, L. M. Parker, and S. J. Keith. 1999. Sildenafil for iatrogenic serotonergic antidepressant medication-induces sexual dysfunction in 4 patients. J. Clin. Psychiatry 60:33–35.
   PubMed Web of Science ®Google Scholar
• M. L. Schrag, and L. C. Wienkers. 2001. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metab. Dispos. 29:70–75.
   PubMed Web of Science ®Google Scholar
• F. H. Segelman, E. Kelton, R. M. Terzi, N. Kucharczy, and R. D. Sofia. 1985. The comparative potency of phenobarbital and five 1,3-propanediol dicarbamates for hepatic cytochrome P450 induction in rats. Res. Commun. Chem. Pathol. Pharmacol. 48:467–470.
   PubMedGoogle Scholar
• M. T. Sheu, A. B. Wu, G. C. Yeh, A. Hsia, and H. O. Ho. 2003. Development of a liquid chromatographic method for bioanalytical applications with sildenafil. J. Chromatogr. B 791:255–262.
   PubMed Web of Science ®Google Scholar
• M. Shou, R. Dai, D. Cui, K. R. Korzekwa, T. A. Bailliet, and T. H. Rushmore. 2001. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J. Biol. Chem. 272:3149–3152.
   Google Scholar
• M. Shou, J. Grogan, J. A. Mancewiez, K. W. Krausz, F. J. Gonzalez, H. V. Gelboin, and K. R. Korzekwa. 1994. Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450–6455.
   PubMed Web of Science ®Google Scholar
• M. Shou, Q. Mei, M. W. Ettore, R. Dai, T. A. Baillie, and T. H. Rushmore. 1999. Sigmoidal kinetic model for two cooperative substrate-binding sites in a cytochrome P450 3A4 active site: An example of the metabolism of diazepam and its derivatives. Biochem. J. 340:845–853.
   PubMed Web of Science ®Google Scholar
• Y. F. Ueng, T. Kuwabara, Y. J. Chun, and F. P. Guengerich. 1997. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370–381.
   PubMed Web of Science ®Google Scholar
• D. K. Walker, M. J. Ackland, G. C. James, G. J. Muirhead, D. J. Rance, P. Wastall, and P. A. Wright. 1999. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29:297–310.
   PubMed Web of Science ®Google Scholar
• R. W. Wang, D. J. Newton, N. Liu, W. M. Atkins, and A. Y. H. Lu. 2000. Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 28:360–366.
   PubMed Web of Science ®Google Scholar
• R. W. Wang, D. J. Newton, T. D. Scheri, and A. Y. H. Lu. 1997. Human cytochrome P450 3A4-catalyzed testosterone 6β-hydroxylation and erythromycin N-demethylation: Competition during catalysis. Drug Metab. Dispos. 25:502–507.
   PubMed Web of Science ®Google Scholar
• J. S. Warrington, R. I. Shader, L. L. von Moltke, and D. J. Greenblatt. 2000. In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions. Drug Metab. Dispos. 28:392–397.
   PubMed Web of Science ®Google Scholar